Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Calico and AbbVie advance antiaging efforts
by Ryan Cross
June 30, 2018
| A version of this story appeared in
Volume 96, Issue 27
AbbVie is boosting its collaboration with the secretive antiaging company Calico, which is backed by Alphabet, Google’s parent company. Both companies will contribute $500 million more to drug discovery efforts that began in 2014. A scientific publication (eLife 2018, DOI: 10.7554/eLife.32733) indicates that the duo is working with a molecule called ISRIB, integrated stress response inhibitor. Other groups previously demonstrated that ISRIB enhances memory and appears to reverse the effects of traumatic brain injury in mice.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter